---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-057233"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:45:44.240289+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics reports 100% efficacy in Phase 2a of HT-001 for EGFRI skin toxicities

## Summary
- Phase 2a CLEER-001 study: 100% of patients achieved primary endpoint; 66% reported reduced pain/itching.
- All patients maintained EGFR inhibitor dosage while on HT-001, preserving cancer treatment.
- Preclinical data showed 56% reduction in hair loss and 58% reduction in facial lesions with preventive HT-001.
- HT-001 uses 505(b)(2) pathway; IND open; NDA submission targeted for 2030.
- No FDA-approved therapy exists for EGFRI-induced cutaneous toxicities; HT-001 seeks first-in-market.

## SEC filing metadata
- accession: 0001213900-25-057233
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390025057233/0001213900-25-057233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390025057233/ea0246748-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-057233
- JSON: https://secwatch.observer/filing/0001213900-25-057233.json
- Plain text: https://secwatch.observer/filing/0001213900-25-057233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.